# A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

> **NCT07123519** · PHASE1 · RECRUITING · sponsor: **China Immunotech (Beijing) Biotechnology Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis (LN)
- Sjogren's Syndrome (SS)
- Inflammatory Myopathy
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Antiphospholipid Syndrome (APS)

## Interventions

- **DRUG:** YTS109 cell

## Key facts

- **NCT ID:** NCT07123519
- **Lead sponsor:** China Immunotech (Beijing) Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-13
- **Primary completion:** 2026-08-13
- **Final completion:** 2027-08-13
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123519, "A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07123519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*